Impact of Age on Survival in Multiple Myeloma Patients
Author Information
Author(s): A Riccardi, O Mora, S Brugnatelli, C Tinelli, R Spanedda, A De Paoli, L Barbarano, M Di Stasi, C Bergonzi, M Giordano, C Delfini, G Nicoletti, E Rinaldi, L Piccininil, D Valentini, E Ascari
Primary Institution: Universita e Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S Matteo, Pavia, Italy
Hypothesis
Age could influence the prognosis of multiple myeloma patients treated with conventional chemotherapy.
Conclusion
Younger patients with multiple myeloma treated with chemotherapy tend to survive longer than older patients.
Supporting Evidence
- 271 out of 341 patients had died by May 1996.
- Median survival for patients aged > 66 years was 31 months, while for those < 66 years it was 44 months.
- Among patients < 55 years, median survival was 57 months.
- 32% of patients < 66 years survived over 72 months compared to 17% of patients > 66 years.
Takeaway
If you're younger when you get treated for multiple myeloma, you might live longer than if you're older.
Methodology
Patients were treated with chemotherapy in a prospective, multicentre, randomized protocol and survival was evaluated based on age groups.
Limitations
The study may not account for all variables affecting survival, such as the type of chemotherapy received.
Participant Demographics
Patients were previously untreated with multiple myeloma, with a median age of 66 years.
Statistical Information
P-Value
0.00095
Statistical Significance
p<0.00095
Want to read the original?
Access the complete publication on the publisher's website